Satellite Symposium: SGLT2 Inhibitors in the Treatment of Cardiovascular Disease, Diabetes, and Chronic Kidney Disease
Saturday, March 23, 2024
6:00 PM – 8:00 PM East Coast USA Time
Location: Orange County Convention Center, Valencia D
CE: 1.5
Number of Hours: 1.5
Activity Type: Knowledge-based
Dinner: 6:00 PM - 6:30 PM ET
This program features patient counseling video vignettes and will focus on the role of the pharmacist in optimizing use of sodium-glucose cotransporter-2 inhibitors in the treatment and management of diabetes, cardiovascular disease, and chronic kidney disease. This activity includes patient counseling vignettes.
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
Learning Objectives:
Explain the interrelationship of cardiovascular disease (CVD), type 2 diabetes (T2D), and chronic kidney disease in the framework of their effect on diagnosis, management, and prognosis
Investigate the sodium-glucose cotransporter-2 (SGLT2) inhibitors that have been shown in randomized controlled clinical trials to treat T2D, CVD, and kidney diseases
Apply the pharmacist’s skill and expertise to counsel patients on the use of SGLT2 inhibitors for optimal outcomes
